AAD "hopeful" for sunscreen rule
This article was originally published in The Rose Sheet
Executive SummaryThe American Academy of Dermatology says it "does not have any specific knowledge about a release date for the sunscreen monograph" but "is hopeful that the FDA will release the sunscreen monograph as soon as possible," noting that in September FDA indicated that it aimed to publish its long-awaited final rule by the year's end. The academy announced Dec. 3 that it is closing down its "Seal of Recognition" program for sunscreens of demonstrated excellence, confident that FDA's updated guidelines are imminent (1"The Rose Sheet" Dec. 7, 2009). "The board did [also] consider the fact that given its low participation levels, the AAD seal program was not meeting its public education goals, which [were] to encourage greater use of more protective sunscreens and increase public awareness of the dangers of excessive sun exposure," AAD President David M. Pariser told "The Rose Sheet" Dec. 4. He noted that the costs associated with the seal program exceeded the revenue it generated, so it contributed no funds to the academy's awareness activities and therefore will not be missed on that count. Through its outreach initiatives, AAD has enabled its members to conduct 1.9 million free skin cancer screenings, detecting more than 188,000 suspicious lesions, including more than 21,500 suspected melanomas
You may also be interested in...
The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.
Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug; FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.